Resonant Capital Advisors, LLC Exelixis, Inc. Transaction History
Resonant Capital Advisors, LLC
- $1.22 Billion
- Q2 2024
A detailed history of Resonant Capital Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Resonant Capital Advisors, LLC holds 13,746 shares of EXEL stock, worth $366,193. This represents 0.03% of its overall portfolio holdings.
Number of Shares
13,746
Previous 13,269
3.59%
Holding current value
$366,193
Previous $314,000
1.91%
% of portfolio
0.03%
Previous 0.03%
Shares
12 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$892 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$790 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$722 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$404 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$336 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $8.57B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...